humira | Media Room | PressRelease.com

Tagged humira

Ankylosing Spondylitis Market Largely Dominated by TNF-Inhibitors, Though Novartis' Cosentyx Enjoyed Significant Year Over Year Gains and a Growing Percent of Rheumatologists Report Off-Label Use of Pfizer's Xeljanz

Press Release Sep 6, 2018

Ankylosing Spondylitis Market Largely Dominated by TNF-Inhibitors, Though Novartis' Cosentyx Enjoyed Significant Year Over Year Gains and a Growing Percent of Rheumatologists Report Off-Label Use of Pfizer's Xeljanz

With no current FDA approved biologics for the treatment of non-radiographic axial spondyloarthropathy, overall penetration of biologics/JAKs is significantly lower than for ankylosing spondylitis; however, when these agents are prescribed, brand usage closely mirrors the ankylosing spondylitis indication, according to a new publication by Spherix Global Insights Read More

Press Release Aug 23, 2018

Pfizer's Xeljanz Begins to Shift the Treatment Paradigm in Ulcerative Colitis (UC) With Early Launch Metrics Largely Favorable for the Brand

The majority of patients started on Xeljanz have failed multiple biologics, but some gastroenterologists see the brand securing a role in the pre-biologic space in the near future, according to the latest quarterly report from Spherix Global Insights Read More

First
Prev

1

Next
Last